JP2017501129A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501129A5
JP2017501129A5 JP2016533150A JP2016533150A JP2017501129A5 JP 2017501129 A5 JP2017501129 A5 JP 2017501129A5 JP 2016533150 A JP2016533150 A JP 2016533150A JP 2016533150 A JP2016533150 A JP 2016533150A JP 2017501129 A5 JP2017501129 A5 JP 2017501129A5
Authority
JP
Japan
Prior art keywords
cell receptor
modified
amino acid
cell
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016533150A
Other languages
English (en)
Japanese (ja)
Other versions
JP6476182B2 (ja
JP2017501129A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066892 external-priority patent/WO2015077607A1/en
Publication of JP2017501129A publication Critical patent/JP2017501129A/ja
Publication of JP2017501129A5 publication Critical patent/JP2017501129A5/ja
Application granted granted Critical
Publication of JP6476182B2 publication Critical patent/JP6476182B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016533150A 2013-11-22 2014-11-21 改変された高親和性ヒトt細胞受容体 Active JP6476182B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
US61/907,887 2013-11-22
PCT/US2014/066892 WO2015077607A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Publications (3)

Publication Number Publication Date
JP2017501129A JP2017501129A (ja) 2017-01-12
JP2017501129A5 true JP2017501129A5 (show.php) 2017-12-28
JP6476182B2 JP6476182B2 (ja) 2019-02-27

Family

ID=53180203

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016533163A Expired - Fee Related JP6697386B2 (ja) 2013-11-22 2014-11-21 改変された高親和性ヒトt細胞受容体
JP2016533150A Active JP6476182B2 (ja) 2013-11-22 2014-11-21 改変された高親和性ヒトt細胞受容体
JP2019190139A Expired - Fee Related JP6970724B2 (ja) 2013-11-22 2019-10-17 改変された高親和性ヒトt細胞受容体
JP2021178468A Pending JP2022023196A (ja) 2013-11-22 2021-11-01 改変された高親和性ヒトt細胞受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016533163A Expired - Fee Related JP6697386B2 (ja) 2013-11-22 2014-11-21 改変された高親和性ヒトt細胞受容体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019190139A Expired - Fee Related JP6970724B2 (ja) 2013-11-22 2019-10-17 改変された高親和性ヒトt細胞受容体
JP2021178468A Pending JP2022023196A (ja) 2013-11-22 2021-11-01 改変された高親和性ヒトt細胞受容体

Country Status (20)

Country Link
US (4) US10023625B2 (show.php)
EP (2) EP3071594A4 (show.php)
JP (4) JP6697386B2 (show.php)
KR (2) KR20160085345A (show.php)
CN (2) CN105899530B (show.php)
AU (4) AU2014352834B2 (show.php)
BR (1) BR112016011567A2 (show.php)
CA (2) CA2930852C (show.php)
DK (1) DK3071593T3 (show.php)
ES (1) ES2729406T3 (show.php)
IL (2) IL245467B (show.php)
MX (3) MX383471B (show.php)
PL (1) PL3071593T3 (show.php)
PT (1) PT3071593T (show.php)
RU (2) RU2729383C2 (show.php)
SA (1) SA516371174B1 (show.php)
SG (2) SG10201804330YA (show.php)
TR (1) TR201908404T4 (show.php)
WO (2) WO2015077607A1 (show.php)
ZA (2) ZA201603116B (show.php)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
CA2645766A1 (en) 2006-04-10 2007-10-25 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2014113490A2 (en) 2013-01-15 2014-07-24 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
EP3071594A4 (en) * 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
FI3352798T3 (fi) * 2015-09-22 2026-02-12 Univ Wuerzburg J Maximilians Menetelmä korkeatasoista ja stabiilia geeninsiirtoa varten lymfosyyteissä
WO2017055635A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
WO2018090057A1 (en) * 2016-11-14 2018-05-17 Fred Hutchinson Cancer Research Center High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof
CA3055983A1 (en) * 2017-03-15 2018-09-20 Fred Hutchinson Cancer Research Center High affinity mage-a1-specific tcrs and uses thereof
BR112019022321A2 (pt) * 2017-04-24 2020-05-26 Ospedale San Raffaele S.R.L. Tcr e peptídeos
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 T細胞レセプター
EP3826626A4 (en) * 2018-07-23 2022-07-06 Magenta Therapeutics, Inc. USE OF ANTI-CD137 ANTIBODY-DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY
EP3938386A1 (en) 2019-03-11 2022-01-19 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
EP4017872A1 (en) * 2019-08-20 2022-06-29 Fred Hutchinson Cancer Center T-cell immunotherapy specific for wt-1
JP2023513706A (ja) * 2020-02-12 2023-04-03 アッヴィ・インコーポレイテッド 二特異性結合分子
EP4142746A1 (en) 2020-04-28 2023-03-08 Achilles Therapeutics UK Limited T cell therapy
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
EP4359511A1 (en) 2021-06-22 2024-05-01 Achilles Therapeutics UK Limited A method for producing antigen-specific t cells
WO2023004289A1 (en) * 2021-07-19 2023-01-26 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
WO1991001754A1 (en) 1989-08-09 1991-02-21 Rhodes Buck A Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
CA2328144A1 (en) 1998-05-19 1999-11-25 Avidex Limited Multivalent t cell receptor complexes
EP1124568B1 (en) 1998-10-21 2007-08-22 Altor BioScience Corporation Polyspecific binding molecules and uses thereof
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1549748B1 (en) 2002-10-09 2014-10-01 Immunocore Ltd. Single chain recombinant t cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
ATE408684T1 (de) 2004-05-19 2008-10-15 Medigene Ltd Verfahren zur verbesserung von t-zellrezeptoren
GB0524477D0 (en) * 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
US8697854B2 (en) * 2008-11-24 2014-04-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
CA2777053A1 (en) * 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
AU2010358291A1 (en) 2010-07-28 2013-02-28 Immunocore Ltd T cell receptors
EP3213765B1 (en) 2010-09-20 2019-08-28 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
EP3071594A4 (en) 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技(上海)有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用

Similar Documents

Publication Publication Date Title
JP2017501129A5 (show.php)
JP2017501130A5 (show.php)
RU2016124179A (ru) СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
JP2016020389A5 (show.php)
JP2019506841A5 (show.php)
JP2019508013A5 (show.php)
JP2019511222A5 (show.php)
EA202090275A2 (ru) Антитела против с5 с улучшенными фармакокинетическими характеристиками
JP2018501197A5 (show.php)
JP2017113019A5 (show.php)
JP2016502515A5 (show.php)
JP2019535763A5 (show.php)
JP2017534638A5 (show.php)
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
JP2017506217A5 (show.php)
FI3525583T3 (fi) Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
JP2009535021A5 (show.php)
JP2018521983A5 (show.php)
JP2019517790A5 (show.php)
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
JP2014532649A5 (show.php)
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
JP2017506669A5 (ja) 膠芽腫の治療に使用するための組成物及びその使用
JP2016530223A5 (show.php)